Aventis Lantus launch
Executive Summary
Sales reps detailing the long-acting insulin product Lantus "reached 50% of the 56,0000 targeted physicians in the first week on the market," Aventis CEO Richard Markham says during Goldman Sachs conference June 13. Lantus was approved over a year ago, but launch was delayed until May 22 while Aventis built sufficient supplies. "Forty-seven out of 50 states have added Lantus to the Medicaid formularies already and we're confident that the other three will soon follow," Markham says. The drug was "approved [for] unrestricted access in the largest U.S. PBM"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth